Effects of AEF0217 in People with Down Syndrome
Part of Brain & nervous system, Genetic & congenital clinical trials.
This study looks at the effects of a medication called AEF0217 in people with Down syndrome. It is for participants who have already completed an earlier study of AEF0217 and their caregivers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have already finished the AEF0217-102 study
- A caregiver must also be part of the study
- You or your caregiver must sign a consent form agreeing to participate
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if an investigational drug called AEF0217 can help improve thinking and daily living skills in people with Down syndrome. It's for ages 16-32 who have a caregiver to support them throughout the trial.
This trial tests if an investigational drug called donanemab can lower amyloid plaques in the brain to slow Alzheimer's disease in adults with Down syndrome. Participants must be 35–50, have elevated brain amyloid, and not have dementia yet.
This study tests whether a supplement that boosts a natural substance called NAD (which helps cells work properly) can slow or stop memory loss in people with Down syndrome. You and your caregiver would visit a clinic for regular checkups and take the supplement daily.
This Phase 1/2 study tests an Alzheimer’s treatment called ACI-24.060 to see if it affects the disease in people with early Alzheimer’s changes. It includes two groups: older adults with early symptoms and people with Down syndrome who also show Alzheimer’s-related changes on brain scans.
This study tests whether a medicine called memantine (already used for memory problems) can help people with Down syndrome think and remember better. Researchers will try different doses to find what works best and is safest.
This study includes people of many ages to help researchers learn more about Trisomy (an extra chromosome condition) in those with and without Down syndrome. It may help improve understanding and future care for people affected by chromosome differences.
Hear when a new Down Syndrome (Trisomy 21) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.